Zacks Research Issues Pessimistic Estimate for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research dropped their Q1 2025 earnings per share (EPS) estimates for shares of Corcept Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. Zacks Research analyst K. Das now expects that the biotechnology company will post earnings of $0.17 per share for the quarter, down from their previous forecast of $0.29. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.36 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q4 2025 earnings at $0.63 EPS and Q1 2026 earnings at $0.45 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $181.89 million during the quarter, compared to analyst estimates of $200.12 million.

CORT has been the subject of a number of other research reports. StockNews.com downgraded Corcept Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, February 28th. Piper Sandler boosted their target price on Corcept Therapeutics from $67.00 to $78.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Corcept Therapeutics in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group lifted their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, January 30th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.75.

Corcept Therapeutics Stock Down 1.9 %

Shares of NASDAQ CORT opened at $58.32 on Monday. The stock has a market capitalization of $6.15 billion, a PE ratio of 46.29 and a beta of 0.61. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The firm has a fifty day moving average of $61.79 and a 200-day moving average of $54.29. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $75.00.

Institutional Investors Weigh In On Corcept Therapeutics

Hedge funds have recently bought and sold shares of the business. Black Diamond Financial LLC boosted its stake in shares of Corcept Therapeutics by 4.0% during the 4th quarter. Black Diamond Financial LLC now owns 5,200 shares of the biotechnology company’s stock valued at $262,000 after buying an additional 200 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in Corcept Therapeutics by 9.5% in the fourth quarter. Quadrant Capital Group LLC now owns 2,969 shares of the biotechnology company’s stock valued at $150,000 after acquiring an additional 257 shares in the last quarter. Summit Investment Advisors Inc. boosted its stake in Corcept Therapeutics by 3.3% during the 4th quarter. Summit Investment Advisors Inc. now owns 8,459 shares of the biotechnology company’s stock valued at $426,000 after acquiring an additional 268 shares during the last quarter. Hancock Whitney Corp grew its holdings in Corcept Therapeutics by 1.2% during the 3rd quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock worth $1,062,000 after acquiring an additional 270 shares in the last quarter. Finally, Arizona State Retirement System increased its position in shares of Corcept Therapeutics by 1.1% in the 4th quarter. Arizona State Retirement System now owns 27,270 shares of the biotechnology company’s stock worth $1,374,000 after purchasing an additional 289 shares during the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company’s stock in a transaction dated Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares in the company, valued at approximately $4,299,174.02. The trade was a 18.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 45,627 shares of company stock worth $2,557,674. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.